At the heart of this discovery lies PIM1, a serine/threonine kinase well-known for its role in promoting prostate tumor growth, survival, and resistance to conventional therapies. Despite the development of various PIM1 inhibitors aimed at curbing its kinase activity, clinical success has been elusive, particularly in patients with solid tumors. The study probes the inadequacies of these conventional inhibitors and shifts the focus towards understanding the multifaceted biology of PIM1. Dr. Warfel’s work reveals that simply inhibiting PIM1’s enzymatic function does not fully neutralize its cancer-supporting properties, as the protein wields influence beyond its traditional kinase signaling.

Classically, kinase inhibitors designed to target PIM1 have been intended to block its enzymatic activity—effectively halting the phosphorylation events that drive tumor progression. However, Warfel’s team discovered that these drugs paradoxically cause an accumulation of PIM1 protein within cancer cells. Rather than being degraded, the surplus protein lingers and continues to facilitate cancer cell survival through kinase-independent mechanisms. This phenomenon results in a paradoxical biological double-edged sword: while inhibiting the enzyme’s catalytic function, the drugs inadvertently empower cancer cells with a fresh lifeline to resist death.

Key to this newly uncovered survival mechanism is the interaction between PIM1 and another protein known as HMGB1, a chromatin-binding factor usually confined to the nucleus. HMGB1 has a pivotal role in orchestrating cellular responses to DNA damage, but when PIM1 protein is abundant, these two form a complex that relocates HMGB1 from the nucleus to the cytoplasm. Once in the cytoplasm, HMGB1 ignites autophagy—a cellular recycling process that allows cancer cells to eliminate dysfunctional organelles, particularly damaged mitochondria.

Damaged mitochondria are notorious sources of reactive oxygen species and oxidative stress, conditions that can precipitate cell death. By facilitating the clearance of these harmful mitochondria, the PIM1-HMGB1 axis effectively lowers oxidative stress, bestowing cancer cells with a remarkable resilience against therapies designed to induce lethal damage. This mitophagy-driven defense mechanism enables prostate cancer cells to survive treatment regimens that would otherwise be effective, thus revealing a sophisticated layer of therapeutic evasion.

The implications of these findings are profound. They underscore a fundamental flaw in the current approach to drug design for kinase targets: the assumption that merely inhibiting the catalytic activity of a protein suffices to halt its oncogenic functions. Dr. Warfel emphasizes that the presence of the PIM1 protein itself—irrespective of its enzymatic activity—can sustain drug resistance, signaling a need for therapies that eliminate the protein entirely rather than merely neutralizing its kinase function.

In response to this challenge, the research team previously engineered a novel class of molecules known as proteolysis-targeting chimeras (PROTACs), specifically designed to induce the degradation of the PIM1 protein. Their lead compound, PIMTAC, capitalizes on the cell’s own proteasomal machinery to selectively tag and destroy PIM proteins, rather than simply inhibiting their kinase activity. Laboratory experiments and mouse model studies demonstrate that PIMTAC significantly enhances cancer cell death by increasing oxidative stress and disrupting the HMGB1-mediated survival pathway, outperforming conventional PIM1 inhibitors.

PIMTAC’s capacity to degrade PIM1 addresses both the signaling-dependent and -independent functions of the protein, offering a more comprehensive treatment strategy. By eliminating the kinase-independent survival effects, this approach holds promise for overcoming the persistent issue of drug resistance that hampers the efficacy of current therapies. The data suggest that this novel method could extend beyond prostate cancer to other malignancies where PIM proteins contribute to disease progression, including breast, lung, and various hematologic cancers.

While the development of PIMTAC represents a significant advance, the research remains in its preclinical phase. Challenges such as optimizing systemic delivery of the relatively large PROTAC molecule and improving its tumor-targeting specificity need to be addressed before clinical trials can commence. However, the insights gleaned from these studies reaffirm the importance of in-depth biological exploration of cancer targets, even those that have been the focus of research for many years.

This work also reflects a broader paradigm shift in oncology drug development. Increasing recognition of non-catalytic roles played by kinases and other oncogenic proteins suggests a future where protein degradation technologies might supersede traditional enzyme inhibition. Dr. Warfel envisions a landscape in which cancer therapeutics not only disable protein functions but remove the underlying protein itself, thereby dismantling multiple cancer-supportive mechanisms simultaneously.

Ultimately, this study epitomizes the continuous innovation and relentless inquiry needed to outsmart cancer’s adaptability. By uncovering a concealed survival pathway and offering a way to dismantle it, researchers add a crucial weapon to the anticancer arsenal. For patients battling advanced prostate cancer, particularly those facing the frustrations of treatment resistance, such advances kindle hope for more effective, durable therapies that can translate to improved outcomes and prolonged survival.

The journey from laboratory breakthrough to clinical application involves numerous hurdles, but endeavors like Dr. Warfel’s offer a compelling blueprint for future cancer research. Exploring the nuanced biology of proteins like PIM1 not only deepens scientific understanding but also fuels the creation of revolutionary treatments with the potential to save lives. This study stands as a testament to the power of reexamining established targets with fresh eyes and cutting-edge techniques, underscoring the importance of basic and translational research in reshaping cancer therapy.

As the medical community continues to explore the complexities of tumor biology, the integration of protein-targeting strategies such as PROTACs will likely play an instrumental role in overcoming therapeutic resistance. The PIM1-HMGB1 interaction and its influence on mitophagy highlight how intricate and multifaceted cancer cell survival mechanisms can be. Future investigations will undoubtedly build upon this foundational work, expanding the horizon of possibilities for precise, effective, and personalized cancer treatment modalities.

Subject of Research: Cells

Article Title: Kinase-independent signaling by PIM1 promotes drug resistance by increasing mitophagy and reducing oxidative stress

News Publication Date: 27-May-2026

Web References:

• Cancer Letters Article: https://www.sciencedirect.com/science/article/pii/S0304383526003745
• Previous related work: https://www.mdpi.com/2073-4409/11/6/1006

References: DOI: 10.1016/j.canlet.2026.218611

Image Credits: Medical University of South Carolina, Photo by Clif Rhodes

Keywords: Kinase inhibitors, Prostate cancer, Autophagy

Chromosomes, the organized bundles of DNA strands within cells, carry the essential genetic instructions that govern cellular behavior. In healthy cells, tightly regulated processes ensure that chromosome numbers are precisely maintained during cell division. However, the unchecked, rapid proliferation characteristic of tumors often results in chromosome missegregation. This leads to aneuploidy, a condition previously correlated with heightened tumor aggressiveness but whose mechanistic underpinnings in therapy resistance remained elusive.

The NYU Langone team approached this challenge by engineering human colon, lung, and eye cell models with induced chromosome abnormalities. Upon exposing these aneuploid cells to reactive oxygen species (ROS)—highly reactive molecules known to inflict severe oxidative DNA damage—they observed a striking survival advantage compared to normal, chromosomally stable cells. This enhanced resilience appeared independent of whether chromosomes were gained or lost, highlighting a fundamental survival strategy employed by chromosomally aberrant cancer cells.

Delving deeper, researchers focused on the protein Poly (ADP-Ribose) Polymerase 1 (PARP1), a key enzymatic player in the DNA damage response pathway. Typically, PARP1 facilitates DNA repair but triggers cell death when DNA damage, such as that induced by oxidative stress, becomes overwhelming. Remarkably, aneuploid cancer cells were found to harbor 50 to 60 percent less PARP1 protein than their euploid counterparts. This deficiency essentially clamps down on the cell’s self-destruct mechanism, enabling damaged cancer cells to survive and propagate despite therapeutic assaults.

Addressing the molecular control behind this phenomenon, the team employed an advanced genome-wide CRISPR screen. This unbiased, systematic gene editing technique pinpointed that lysosomal stress—a disruption in the cell’s recycling centers—activates CCAAT/enhancer-binding protein beta (CEBPB). This transcription factor then suppresses PARP1 gene expression, further dampening cell death pathways. This intricate signaling axis reveals how chromosome missegregation indirectly rewires gene regulation to favor cancer cell survival.

Mouse models provided compelling functional evidence as well. Lowering PARP1 levels enhanced metastatic spread, allowing cancer cells to colonize distant organs more efficiently. Conversely, restoring PARP1 expression curtailed this invasive capability. These preclinical results were corroborated by clinical data, which demonstrated significantly reduced PARP1 levels in metastatic colorectal tumors compared to their primary tumor origins.

This new insight reframes our understanding of aneuploidy’s role in cancer pathology. It not only fuels tumor growth but actively rewires cellular stress responses to evade oxidative damage-induced death. Consequently, these findings suggest that therapeutic strategies aimed at restoring PARP1 function, or targeting key nodes of the lysosomal stress response, could dismantle this survival advantage, limiting cancer progression and metastasis.

The study’s senior author, Dr. Teresa Davoli, emphasizes the significance of these findings: “By illuminating how aneuploidy contributes to both tumor proliferation and metastatic behavior through PARP1 suppression, we open new therapeutic possibilities targeting these pathways.” The collaborative effort included scientists from various domains within NYU Langone Health’s Institute for Systems Genetics and Perlmutter Cancer Center, underscoring the interdisciplinary nature of this breakthrough.

Looking ahead, the research team is keen to investigate how this aneuploidy-driven PARP1 reduction influences responsiveness to existing cancer drugs, particularly PARP inhibitors which are already deployed clinically. Their initial observations suggest that aneuploid tumors might display unique vulnerabilities or resistances to these agents, which could inform precision medicine approaches moving forward.

Importantly, these revelations come amidst a broader quest to understand the genetic and molecular diversity of cancers. Aneuploidy is a hallmark of many malignancies, yet its functional consequences have remained enigmatic. By unraveling how chromosomal errors shift the balance between cell death and survival, this study provides a pivotal piece in the cancer puzzle, potentially sparking innovative drug development pipelines designed to exploit these vulnerabilities.

This comprehensive research was supported by multiple esteemed funding bodies including the National Institutes of Health, Cancer Research UK, and the Mark Foundation for Cancer Research. The convergence of cutting-edge experimental methods, rigorous genetic screening, and translational mouse models illustrates the paradigm of modern biomedical research advancing cancer biology.

As the landscape of cancer therapeutics evolves, understanding the interplay between chromosomal instability and cellular signaling pathways will be key to overcoming resistance mechanisms. The discovery that aneuploidy-induced PARP1 suppression significantly drives oxidative stress resistance underscores this intricate interplay, promising to reshape future strategies for combating resistant and metastatic cancers.

Subject of Research: Cells

Article Title: Molecular Cell PARP1 Suppression Drives ROS Resistance in Aneuploid Cancer Cells

News Publication Date: 7-May-2026

Keywords: Cancer cells, Aneuploidy, Chromosome abnormalities, PARP1, Oxidative stress, Reactive oxygen species, Cell death, Lysosomal stress, CEBPB, Metastasis, DNA damage response, CRISPR screen

Apoptosis, a meticulously regulated form of cell death, is fundamental to the preservation of cellular homeostasis. It orchestrates the systematic dismantling of damaged, infected, or excess cells, thus maintaining tissue integrity and function while preventing malignancy. Perturbations in this mechanism — notably the failure to trigger apoptotic pathways — are a hallmark of cancer, facilitating unchecked cellular proliferation and tumor progression. Current cancer therapies, including chemotherapy and radiotherapy, often aim to reactivate apoptosis by inducing cellular stress and DNA damage. Yet, a common cause of therapeutic failure is the tumor’s ability to thwart these signals, highlighting a need for deeper molecular understanding.

Central to the apoptotic machinery are proteins from the Bcl-2 family, which serve as pivotal arbiters balancing cell survival and death. Among these, Bax is a pro-apoptotic effector that, upon activation, oligomerizes to form pores within the mitochondrial outer membrane—a decisive event that commits a cell to apoptosis by releasing cytochrome c and activating downstream caspases. In contrast, Bcl-2, a well-known anti-apoptotic counterpart, acts as a guardian of mitochondrial integrity by sequestering and inhibiting Bax’s apoptotic activity. Overexpression of Bcl-2 is implicated in approximately 50% of human cancers and is strongly associated with poor clinical outcomes due to its role in fostering resistance to cell death.

The researchers employed advanced neutron scattering techniques—providing exceptional resolution and sensitivity—to dissect the interactions between Bcl-2 and Bax at the mitochondrial membrane interface. Their findings challenge earlier models which posited a simple one-to-one inhibition of Bax by Bcl-2. Instead, the study elucidates a mechanism whereby a single Bcl-2 molecule can simultaneously engage multiple Bax proteins, thereby amplifying the inhibition of apoptosis more effectively than previously appreciated. This oligomerization-driven suppression elucidates how cancerous cells can maintain survival advantages even with only modest upregulation of Bcl-2, explaining why subtle variations in Bcl-2 levels can profoundly impact tumor resilience.

The mitochondrial membrane environment itself emerged as a critical factor modulating protein interactions. The lipid composition, particularly the presence of cardiolipin—a phospholipid exclusive to mitochondrial membranes—was shown to influence Bax’s ability to oligomerize and induce pore formation. Cardiolipin fosters membrane curvature and provides a favorable scaffold for Bax activation; however, the anti-apoptotic potency of Bcl-2 remains formidable enough to counteract apoptotic signals even in cardiolipin-rich membranes. This highlights the nuanced biochemical crosstalk dictating cell fate decisions, suggesting that therapeutic strategies could target not only protein-protein interactions but also the lipid milieu of mitochondria.

Beyond providing critical mechanistic insight, these discoveries have profound therapeutic implications. By delineating the multi-faceted inhibition of Bax by Bcl-2, the study opens new paradigms for drug development aimed at dismantling cancer cell defenses. Targeting the oligomerization surfaces or the anchoring interactions of Bcl-2 could disrupt its capacity to neutralize Bax, thereby reinstating the apoptotic pathway and sensitizing tumors to existing treatments. This avenue offers substantial promise in overcoming resistance mechanisms that have long frustrated effective cancer therapy.

Lead author Gerhard Gröbner, professor at the Department of Chemistry, Umeå University, emphasizes the translational potential of these findings: “Our work provides a refined understanding of the molecular chess game played between pro- and anti-apoptotic proteins at the mitochondria. By revealing how Bcl-2 leverages oligomerization to amplify its protective role, we identify vulnerabilities that can be exploited to tip the balance back towards cell death in cancer cells.” This insight elevates the scientific community’s capacity to design precision medicines that selectively dismantle tumor survival strategies without harming healthy cells.

Collaboration was integral to this pioneering research, with contributions from notable institutions including Lund University, the European Spallation Source (ESS) in Lund, the ISIS Neutron and Muon Source and Diamond Light Source in the United Kingdom, and the Institut Laue-Langevin (ILL) in France. The interdisciplinary approach combined biophysical experiments, structural biology, and membrane biochemistry to achieve a comprehensive characterization of these apoptosis regulators at atomic and molecular scales. This synergy underscores the power of international scientific cooperation in tackling complex biomedical challenges.

The methodology harnesses the unique capabilities of neutron scattering to probe proteins embedded in lipid membranes, a formidable technical challenge given the dynamic nature and structural complexity of membrane proteins. Unlike traditional methods such as X-ray crystallography, neutron-based experiments allow researchers to capture native-like states and functional conformations of protein assemblies within lipid bilayers. This methodological advance has been pivotal in unraveling the oligomerization patterns of Bax and its inhibition by Bcl-2, setting new standards for probing membrane protein interactions in a physiologically relevant context.

Such fundamental research into mitochondria-mediated apoptosis not only elucidates cancer cell biology but also informs our understanding of numerous other diseases where apoptosis is dysregulated, including neurodegenerative disorders and autoimmune conditions. By sharpening our understanding of how cells decide life or death, this work enriches the broader biomedical landscape and inspires innovative therapeutic designs that could mitigate a spectrum of pathologies.

Looking forward, this research paves the way for the development of novel molecules designed to disrupt Bcl-2’s multifaceted binding to Bax. Pharmacological modulation of Bcl-2/Bax interactions could restore apoptosis in refractory tumor cells, thereby enhancing the efficacy of conventional cancer therapies. Furthermore, understanding how mitochondrial lipid composition modulates these protein interactions offers an additional therapeutic axis, potentially enabling combinatorial approaches that target both protein and membrane components to sensitize cancers to cell death.

In summary, the study propels the field closer to overcoming one of cancer’s most formidable defense mechanisms. By charting the molecular landscape of Bax inhibition through Bcl-2 oligomerization on mitochondrial membranes, researchers have illuminated a critical survival pathway hijacked by tumors. This knowledge sparks hope for novel, more effective treatments that can circumvent therapy resistance, ultimately improving patient outcomes and extending survival for those afflicted by stubborn malignancies. The intricate dance of proteins on mitochondrial surfaces now stands revealed as a key battlefield in the ongoing war against cancer.

Subject of Research: Cells

Article Title: Avoiding Mitochondrial Apoptosis by the Bcl-2-Driven Bax Oligomerization on Membrane Surfaces

News Publication Date: 18-Feb-2026

Web References:
http://dx.doi.org/10.1021/acschembio.5c00913

Image Credits: Photo: Mattias Pettersson, Umeå University

Keywords: Mitochondrial Apoptosis, Bcl-2, Bax, Cancer Resistance, Protein Oligomerization, Neutron Scattering, Mitochondrial Membrane, Cardiolipin, Programmed Cell Death, Cancer Therapy, Protein-Protein Interaction, Membrane Biochemistry

Central to their discovery is the recognition that the pancreatic tumor microenvironment (TME) is no passive bystander but an active architect of cancer cell resilience. The TME surrounding PDAC is distinguished by two harsh features: a scarcity of oxygen due to scant blood vessel formation, and a distinctive metabolic composition of the interstitial fluid bathing tumor cells. These conditions collectively create a profoundly hostile environment within which PDAC cells must survive. Through meticulous in vitro experimentation mimicking these microenvironmental factors, the research team illuminated how hypoxia—or oxygen deprivation—activates hypoxia-inducible factor-2 (HIF-2), a transcription factor that orchestrates an adaptive response to low oxygen that paradoxically shields PDAC cells from ferroptosis.

Ferroptosis operates through iron-mediated lipid peroxidation, culminating in catastrophic membrane damage and cell death. A critical countermeasure within the cell is glutathione—a potent antioxidant molecule that neutralizes lipid peroxides via the enzyme glutathione peroxidase 4 (GPX4). Drugs like erastin and RSL-3 induce ferroptosis by interrupting glutathione synthesis or directly inhibiting GPX4, respectively. Intriguingly, despite their efficacy in inducing ferroptosis in KRAS-mutant cancers, these compounds fail to exert similar cytotoxicity in PDAC cells cultured under hypoxic conditions combined with PDAC-specific metabolite profiles.

This unexpected outcome sparked deeper inquiry. The researchers utilized a specialized culture medium designed to replicate the interstitial fluid of PDAC tumors, provided by the lab of Alex Muir at Ludwig Chicago. When PDAC cells under hypoxic stress were grown in this medium and exposed to erastin, they demonstrated pronounced resistance to ferroptosis, illustrating an intricate interplay between oxygen sensing and metabolic cues from the TME.

Further molecular dissection revealed that HIF-2 activation enhances the cellular uptake and synthesis of glutathione by upregulating transporters and enzymes critical for glutathione biosynthesis. Simultaneously, HIF-2 promotes mitophagy—the selective degradation of mitochondria—thereby reducing mitochondrial reactive oxygen species (ROS) production. This diminishes the initiation of lipid peroxidation, effectively dampening the ferroptotic cascade before it can irreversibly compromise cellular membranes.

These dual protective strategies underscore the sophistication of PDAC cells in circumventing ferroptosis: they not only bolster antioxidant defenses but also minimize pro-ferroptotic ROS generation. The findings offer a plausible explanation for the clinical intractability of PDAC to ferroptosis-inducing agents, in stark contrast to other KRAS-driven malignancies like kidney cancer where HIF-2 sensitizes tumors to ferroptotic death.

Chi Van Dang emphasizes the translational potential of this research, noting that targeting the biochemical pathways activated by HIF-2 could sensitize pancreatic tumors to ferroptotic therapies previously deemed ineffective. This strategy highlights an emerging paradigm in cancer treatment that integrates environmental manipulation with targeted molecular intervention, potentially transforming outcomes for a cancer type that has long defied meaningful therapeutic progress.

Moreover, this study solidifies the imperative for cancer research to move beyond traditional two-dimensional cell culture models and consider the native tumor ecosystem—encompassing oxygen gradients, nutrient availability, and stromal context—to fully understand tumor biology and therapeutic susceptibility.

The implications extend beyond PDAC, as ferroptosis modulation in the context of hypoxia is relevant to many solid tumors characterized by hypoxic niches and aberrant metabolic states. Future investigations will likely probe whether combining HIF-2 inhibitors or modulators of mitochondrial homeostasis with ferroptosis inducers can overcome resistance in PDAC and other cancers.

This groundbreaking study received funding and support from the Ludwig Institute for Cancer Research, the University of Pennsylvania, and the U.S. National Institutes of Health. Chi Van Dang holds the dual role of CEO and Scientific Director at Ludwig and Bloomberg Distinguished Professor of Cancer Medicine at Johns Hopkins University, further strengthening the translational bridge between bench research and clinical oncology.

Through an elegant blend of molecular biology, tumor physiology, and metabolic modeling, the research offers renewed hope in demystifying PDAC’s resistance mechanisms. As scientists delve deeper into the nexus of hypoxia, metabolism, and ferroptosis, the prospect of effective, targeted therapies against one of the deadliest cancers becomes increasingly tangible.

Subject of Research: Mechanisms of ferroptosis resistance in pancreatic ductal adenocarcinoma (PDAC) mediated by hypoxia-inducible factor-2 (HIF-2)

Article Title: [Not explicitly provided in the source content; article published in Molecular Cell]

News Publication Date: April 2, 2026

Web References:

• Ludwig Institute for Cancer Research: http://www.ludwigcancerresearch.org
• Molecular Cell article: https://www.cell.com/molecular-cell/fulltext/S1097-2765(26)00163-2

References:

• Research article detailing HIF-2 mediated ferroptosis resistance in PDAC in Molecular Cell

Image Credits: Ludwig Cancer Research

Keywords: Pancreatic ductal adenocarcinoma, PDAC, ferroptosis, hypoxia, HIF-2, KRAS mutations, tumor microenvironment, glutathione, GPX4, mitophagy, reactive oxygen species, lipid peroxidation

Riboflavin, an essential micronutrient that humans cannot synthesize, must be obtained through dietary sources such as dairy, eggs, meat, and green vegetables. Once absorbed, the vitamin is metabolized into active cofactors that protect cellular components from oxidative damage. While this protective function is beneficial for maintaining healthy cell integrity, the team at RVZ has demonstrated that the same mechanisms also shield malignant cells, enabling their survival under conditions that would typically induce cell death.

Ferroptosis differs fundamentally from other forms of programmed cell death like apoptosis or necrosis. It is triggered by an accumulation of iron-dependent lipid peroxides, which leads to catastrophic membrane damage and ultimately the demise of the affected cell. This process has emerged as a pivotal biological mechanism not only in cancer but also in various neurodegenerative diseases and tissue injuries. The central mystery has been understanding how cancer cells circumvent ferroptosis to persist and proliferate uncontrollably.

The study highlights the role of FSP1 (ferroptosis suppressor protein 1), a critical enzyme that mitigates ferroptosis by maintaining antioxidant defenses inside the cell. Riboflavin-derived cofactors are indispensable for the enzymatic functions of FSP1, meaning that vitamin B2 metabolism is directly linked to the cancer cell’s ability to dodge ferroptotic death. Using advanced genome editing tools and cellular models, the researchers observed that disrupting riboflavin metabolism sensitized cancer cells to ferroptosis, thereby undermining their survival advantage.

This finding suggests that targeting the riboflavin metabolic pathway might represent a novel and effective strategy to selectively induce ferroptosis in cancer cells without affecting normal cells. Despite this potential, a significant challenge remains: no specific inhibitors of the metabolic enzymes involved in vitamin B2 processing have yet been identified or developed for clinical use.

To overcome this barrier, the research team explored the use of roseoflavin, a naturally occurring analog of riboflavin produced by certain bacteria. Roseoflavin mimics vitamin B2 but can interfere with its metabolic functions. Laboratory experiments demonstrated that roseoflavin, even at low concentrations, could trigger ferroptosis in cancer cells. This exciting result provides proof of concept that metabolic inhibition of riboflavin-dependent pathways can be harnessed to provoke ferroptotic cell death selectively, thereby laying the groundwork for future cancer therapies based on ferroptosis induction.

Looking ahead, the researchers are focused on refining and developing more potent and selective inhibitors of the riboflavin metabolic machinery. These next-generation molecules will be evaluated in preclinical models to assess their therapeutic efficacy and safety profile. Such developments could mark a paradigm shift in oncological treatment, especially for tumors that have developed resistance to conventional therapies.

Professor José Pedro Friedmann Angeli, leader of the research group, emphasized the broader implications of their findings. “Ferroptosis is not just critical in cancer biology but is increasingly recognized as a contributing factor in diverse pathological conditions, including neurodegeneration, ischemia-reperfusion injury, and post-transplant tissue damage,” he explained. Thus, an improved understanding of how vitamin B2 metabolism influences ferroptosis could also have significant repercussions in treating a variety of diseases beyond oncology.

The mechanistic insights gained from this study underscore the complex interplay between micronutrient metabolism and cell death regulation, enriching our molecular understanding of tumor biology. This intersection of metabolism and cell fate decisions represents a fertile ground for discovering biomarkers that can predict response to ferroptosis-based therapies as well as for the development of combination treatments that sensitize tumors to iron-dependent oxidative stress.

The study’s funding was provided by the German Research Foundation’s priority programme SPP2306, dedicated to ferroptosis research from molecular basics to clinical applications. Additionally, significant support came from the DeciFerr project, led by Professor Friedmann Angeli and backed by the European Research Council through an ERC Consolidator Grant awarded in May 2024. This robust financial backing highlights the recognized importance and cutting-edge nature of the work in this emerging field.

While the immediate focus remains on exploiting the riboflavin-FSP1 axis to combat cancer, ongoing research may unlock further therapeutic windows for managing neurodegenerative diseases such as Alzheimer’s and Parkinson’s, where ferroptotic mechanisms contribute to neuronal loss. The possibility of modulating ferroptosis bi-directionally—either enhancing it to kill cancer cells or suppressing it to preserve vulnerable neurons—illustrates the transformative potential of understanding this metabolic pathway in unprecedented detail.

As research progresses, the discovery that a simple vitamin like B2, commonly taken for granted as a dietary supplement, is intricately woven into the fundamental processes governing cell death resistance challenges previous assumptions. It invites clinicians, biochemists, and pharmacologists alike to re-examine the role of metabolism in cancer and develop new therapeutic paradigms to improve patient outcomes worldwide.

Subject of Research: Cells
Article Title: Riboflavin metabolism shapes FSP1-driven ferroptosis resistance
News Publication Date: 13-Mar-2026
Web References: http://dx.doi.org/10.1038/s41556-025-01856-x
References: Skafar et al., Riboflavin metabolism shapes FSP1-driven ferroptosis resistance, Nature Cell Biology, 2026
Image Credits: University of Würzburg / Rudolf Virchow Centre
Keywords: vitamin B2, riboflavin metabolism, ferroptosis, cancer therapy, programmed cell death, FSP1, roseoflavin, oxidative stress, lipid peroxidation, cancer resistance, translational cell biology, ferroptosis inhibitor

Non-small cell lung cancer represents the majority of lung cancer cases, notorious for its high metastatic potential and poor prognosis. Despite therapeutic advances, the underlying cellular behavior enabling tumor cells to migrate and invade under stress remains an enigma. Tumor microenvironments often become hostile due to scarce nutrients, yet cancer cells show a remarkable ability to adapt and survive, contributing to disease progression. This latest research illuminates how NSCLC cells harness autophagy—a self-digestion process—to power their migration during such hostile conditions.

Central to this adaptive response is NDR2 (Nuclear Dbf2-related kinase 2), identified as a master regulator supporting autophagosome formation. Autophagosomes are double-membrane vesicles that encapsulate intracellular components for degradation, essential for cellular homeostasis and survival during nutrient limitations. The precise regulatory mechanisms behind autophagosome biogenesis in migrating cancer cells have remained elusive until now. The research uncovers NDR2’s direct involvement in orchestrating key molecular players of this pathway.

LC3 (Microtubule-associated protein 1 light chain 3), a hallmark of autophagosomes, must be conjugated to autophagic membranes to drive vesicle elongation, a critical step in autophagy. ATG9A, another pivotal autophagy-related protein, traffics membrane sources necessary for autophagosome expansion. This study demonstrates that NDR2 positively regulates the levels and functional activity of both LC3 and ATG9A, ensuring efficient autophagosome formation under starvation stress. These findings intricately link kinase signaling with membrane dynamics in NSCLC cells.

Through a combination of molecular and cellular assays, the authors detail how knocking down NDR2 expression severely impairs LC3 lipidation and ATG9A trafficking, leading to defective autophagosome biogenesis. Without functional autophagy, NSCLC cells exhibit reduced motility and compromised capacity to migrate in nutrient-poor conditions. This phenotype highlights autophagy’s essential role as a facilitator rather than a mere survival mechanism, actively promoting cell migration during metastasis.

The study further explores the spatiotemporal coordination of NDR2 activity, revealing its localization alongside autophagy initiation sites within the cell. This strategic positioning enables NDR2 to fine-tune autophagic flux precisely where membrane nucleation and elongation occur. Such spatial regulation underscores the signaling complexity that tumor cells exploit to adapt swiftly to environmental challenges, thus sustaining aggressive phenotypes.

Importantly, this research elucidates how metabolic stress imposed by starvation paradoxically enhances cancer cell invasiveness via autophagy upregulation. By fueling autophagosome biogenesis, NDR2 enables NSCLC cells not only to maintain energy homeostasis but also to remodel their cytoskeleton and adhesion machinery for efficient migration. This dual role underscores autophagy’s multifaceted contribution beyond recycling cellular components, positioning it as a key driver of metastasis.

The findings propel forward the notion that disrupting NDR2-dependent autophagy pathways could represent a viable therapeutic strategy. Targeting the molecular crosstalk between NDR2, LC3, and ATG9A may disable cancer cell adaptation under nutrient stress, effectively curtailing metastasis. Given that autophagy inhibitors are already being tested in clinical settings, understanding this nuanced regulation offers a refined approach to sensitize tumors to existing therapies.

Moreover, these discoveries prompt a broader reevaluation of autophagy’s role in cancer biology. While traditionally viewed as a cytoprotective mechanism, its direct involvement in enabling cell migration highlights a complex interplay that may vary across tumor types and environmental contexts. This paradigm shift advocates for more targeted research exploring autophagic regulators like NDR2 as multifunctional oncogenic mediators.

This study also raises compelling questions about the potential involvement of NDR2 in other cancers where autophagy and migration intersect under metabolic stress. Expanding this research could reveal conserved signaling pathways exploitable for broader cancer treatment strategies. Additionally, investigating how NDR2-mediated autophagy interfaces with other tumor microenvironment factors such as hypoxia, immune evasion, and extracellular matrix remodeling remains an exciting frontier.

In summary, the research articulated by Biojout et al. reveals that NDR2 acts as a linchpin in NSCLC cell migration under starvation by orchestrating autophagosome biogenesis through LC3 and ATG9A regulation. This mechanistic insight significantly advances our grasp of metastatic processes in nutrient-deprived tumor environments. Therapeutically, targeting NDR2 and its autophagic circuit holds substantial promise in hindering NSCLC progression and improving patient outcomes.

The study’s in-depth molecular analyses combined with functional assays produce a robust framework for future drug development aimed at autophagy regulation. As cancer metastasis continues to be a formidable obstacle, understanding and exploiting vulnerabilities like the NDR2-autophagy axis may revolutionize interventions and save countless lives globally. This transformative research exemplifies the power of integrative biology to decode complex cancer behaviors.

As the scientific community absorbs these findings, the challenge moving forward will be translating this knowledge into clinically effective therapies. Focused efforts on drug discovery targeting kinases like NDR2 and autophagy machinery, alongside patient stratification based on autophagic profiles, will be critical. The convergence of molecular biology and therapeutic innovation marks an exhilarating new chapter in lung cancer research driven by this pivotal study.

In the relentless quest to outsmart cancer’s adaptability, unraveling the molecular circuitry that supports cell migration under metabolic duress is a decisive breakthrough. NDR2’s central role in regulating autophagy to fuel NSCLC invasion highlights novel vulnerabilities in tumor cell survival strategies. This knowledge not only enriches our understanding of cell biology but ignites hope for more effective treatments targeting the dynamic tumor microenvironment.

By elucidating how cancer cells co-opt autophagy machinery to overcome starvation and migrate, this research bridges fundamental molecular insights with clinical imperatives. It sets the stage for a new generation of anticancer approaches aiming at the intersection of metabolism, signaling, and cellular trafficking. The implications of these discoveries will undoubtedly ripple through cancer biology and therapy, galvanizing further innovations.

As researchers continue to unravel the complex networks governing tumor cell behavior, the role of kinases like NDR2 in modulating autophagy emerges as an exciting frontier. This study catalyzes fresh perspectives on targeting metabolic stress responses in cancer, emphasizing the nuanced interplay between survival pathways and metastatic potential. Altogether, these insights herald transformative possibilities in combating one of humanity’s deadliest diseases.

Subject of Research: Regulation of non-small cell lung cancer cell migration under starvation conditions through autophagosome biogenesis mediated by NDR2, LC3, and ATG9A.

Article Title: NDR2 regulates non-small cell lung cancer cell migration under starvation by supporting autophagosome biogenesis through LC3 and ATG9A regulation.

Article References:
Biojout, T., Bergot, E., Taylor, J. et al. NDR2 regulates non-small cell lung cancer cell migration under starvation by supporting autophagosome biogenesis through LC3 and ATG9A regulation. Cell Death Discov. (2025). https://doi.org/10.1038/s41420-025-02889-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02889-9

The newly identified lncRNA, RP11-544M22.13, emerges as a pivotal regulatory molecule orchestrating glycolysis, the metabolic pathway leveraged aggressively by cancer cells to fuel their growth and survival. Xiong, Zhang, Pan, and their colleagues have detailed how this lncRNA modulates metabolic reprogramming in NSCLC, augmenting glycolysis in a manner that directly confers resistance to cisplatin-based therapy. Intriguingly, this metabolically driven resistance mechanism challenges conventional views that primarily attribute chemoresistance to DNA repair alterations or efflux pump overexpression.

At the cellular level, the elucidation of RP11-544M22.13’s role reveals a sophisticated regulatory network. This lncRNA appears to act as a molecular scaffold or regulator enhancing key glycolytic enzymes’ expression and activity, thereby accelerating the metabolic flux of glucose to lactate, even in oxygen-rich conditions—a phenomenon known as the Warburg effect. This augmented glycolysis not only sustains the energetic and anabolic demands of tumor cells but also creates a microenvironment hostile to cisplatin efficacy, possibly through alterations in intracellular pH, redox status, and drug uptake.

The research team employed cutting-edge transcriptomic and metabolomic profiling combined with rigorous in vitro and in vivo models to dissect the functional implications of RP11-544M22.13 expression. Knockdown experiments demonstrated a significant re-sensitization of NSCLC cells to cisplatin upon suppression of this lncRNA, strongly supporting its direct involvement in mediating therapeutic resistance. Conversely, overexpression models confirmed elevated glycolytic rates and concomitant resistance patterns, highlighting RP11-544M22.13 as a bona fide oncogenic metabolic modulator.

Mechanistically, the identification of RP11-544M22.13’s interaction with key regulatory proteins and metabolic enzymes unveils an intricate feedback loop where this RNA species likely influences transcriptional and post-transcriptional events. For instance, RP11-544M22.13 may stabilize mRNAs encoding critical enzymes such as hexokinase 2 (HK2) or pyruvate kinase M2 (PKM2), both integral to glycolytic progression and often upregulated in cancer. This mode of action exemplifies the increasingly appreciated role of lncRNAs as dynamic regulators in cancer biology, transcending their previously underestimated ‘non-coding’ categorization.

Importantly, these findings carry profound clinical implications. Chemoresistance has long remained a formidable barrier in NSCLC management, with limited therapeutic options upon failure of first-line cisplatin-based regimens. Targeting RP11-544M22.13 or its downstream metabolic axis opens the gateway to novel combinatorial therapies where metabolic vulnerabilities of tumor cells are exploited to overcome drug resistance. Conceptualizing inhibitors or RNA-based therapeutics specifically designed to antagonize RP11-544M22.13 could restore cisplatin sensitivity and improve survival rates.

Furthermore, this study underscores the importance of metabolic biomarkers in guiding personalized oncology. Quantitative assessment of RP11-544M22.13 levels could function as a predictive biomarker, identifying patients likely to exhibit primary or acquired resistance to cisplatin. This strategic biomarker-driven approach aligns with precision medicine goals, allowing clinicians to tailor treatment regimens based on tumor metabolic profiling rather than relying on empirical chemotherapy alone.

Beyond NSCLC, this paradigm may extend to other malignancies where glycolysis-driven chemoresistance is evident. The universality of metabolic rewiring in cancer suggests that lncRNAs like RP11-544M22.13 could serve as master regulators across diverse tumor types. Consequently, the translational potential of this research is vast, warranting broader investigative efforts aimed at lncRNA-mediated metabolic control mechanisms.

Technologically, the integration of high-throughput sequencing, RNA interference, CRISPR gene editing, and metabolic assays fostered a comprehensive understanding of RP11-544M22.13’s functions. Such multidisciplinary approaches exemplify the future trajectory of cancer biology research wherein genomics meets metabolomics to unravel complex phenotypes and identify actionable targets.

The characterization of RP11-544M22.13 also offers insights into noncoding genome functionality, which has historically been deemed ‘junk DNA’. This growing recognition of lncRNAs as key players in oncogenic pathways redefines molecular oncology, further justifying large-scale efforts like ENCODE to decode the noncoding genome’s regulatory landscapes.

In summary, the revelation of lncRNA RP11-544M22.13 as a glycolysis enhancer driving cisplatin resistance revolutionizes our perception of metabolic contributions to chemoresistance in NSCLC. By illuminating this link, the study pioneers a new frontier in therapeutic strategy development focused on metabolic modulation and RNA biology. If harnessed effectively, these advances promise to transform clinical practice, offering renewed hope for patients grappling with resistant lung cancer.

As research continues to unravel the complexities of metabolic regulation in cancer, the identification of RP11-544M22.13 pushes the envelope, advocating for integrative cancer therapies that combine metabolic inhibitors with conventional chemotherapeutics. This holistic approach may ultimately overcome the longstanding challenge of chemoresistance and lead to durable remission for many.

The publication of these findings in Cell Death Discovery further emphasizes their significance, as the journal is renowned for disseminating discoveries that redefine cellular and molecular underpinnings of disease. Given the global burden of NSCLC and the critical need for novel interventions, the spotlight on RP11-544M22.13 heralds a momentous leap forward.

Future investigations will need to explore how RP11-544M22.13 interplays with other metabolic and signaling networks, including hypoxia-inducible factors, PI3K/Akt pathway, and epigenetic regulators. Understanding these intersections will deepen our grasp of tumor adaptability and resistance evolution.

In addition, clinical trials assessing the safety and efficacy of agents targeting the RP11-544M22.13 axis are eagerly anticipated. The transition from bench to bedside will mark a definitive step toward precision oncology tailored to tumor metabolism.

Ultimately, the discovery of RP11-544M22.13 exemplifies the transformative power of RNA biology in cancer management. As scientists continue to decode the intricacies of tumor metabolism, lncRNAs stand out as promising therapeutic entry points, offering fresh avenues to surmount the formidable challenge of chemoresistance.

Subject of Research:
The study investigates the role of a novel long non-coding RNA, RP11-544M22.13, in promoting glycolysis-mediated cisplatin resistance in non-small cell lung cancer.

Article Title:
A novel lncRNA RP11-544M22.13 enhances glycolysis-induced cisplatin resistance in non-small cell lung cancer.

Article References:
Xiong, J., Zhang, H., Pan, Z. et al. A novel lncRNA RP11-544M22.13 enhances glycolysis-induced cisplatin resistance in non-small cell lung cancer. Cell Death Discov. (2025). https://doi.org/10.1038/s41420-025-02873-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02873-3

The study underscores the alarming reality that chemotherapy is often rendered ineffective due to the cancer cells’ ability to adapt and resist treatment. LUSC cells exhibit a robust survival strategy, making the identification of molecular mechanisms like the FXR1-FUBP1 axis essential in understanding and dismantling these defenses. FXR1, a member of the heterogeneous ribonucleoprotein (hnRNP) family, has been implicated in regulating various cellular processes, including RNA metabolism, cell proliferation, and apoptosis. Its interaction with FUBP1, a known regulator of c-Myc, is particularly significant in the context of cancer biology.

In the context of their study, Liang et al. meticulously employed various experimental techniques, including Western blotting and RNA sequencing, to unravel the mechanisms driving chemotherapy resistance. They demonstrated that FXR1 facilitates the stabilization of FUBP1, thus enhancing its interaction with c-Myc mRNA. This stabilization results in increased expression of c-Myc, a pivotal transcription factor that drives cell proliferation and survival, contributing further to chemoresistance observed in LUSC.

The current landscape of chemotherapy effectiveness is grim, with many patients experiencing progression of their disease despite treatment. This stagnation underscores a pressing need for innovative strategies that can sensitize these cancer cells to conventional therapies. The elucidation of the FXR1-FUBP1 axis opens new avenues for targeted therapeutic interventions. By inhibiting FXR1 or disrupting its association with FUBP1, it may be possible to destabilize c-Myc levels, thereby re-sensitizing LUSC cells to chemotherapeutic agents.

Moreover, the implications of this research stretch beyond merely improving clinical outcomes for LUSC patients. It serves as a prototype for similar investigations into other cancer types where chemotherapy resistance poses a significant barrier. The findings emphasize the importance of a molecular approach to understanding tumor biology, prompting researchers and clinicians alike to consider more personalized treatment regimens.

One of the most compelling aspects of this research is the potential for the development of novel therapeutic agents aimed specifically at the components of the FXR1-FUBP1 axis. The targeted inhibition of these proteins could prove to be a game-changer in overcoming the mechanisms responsible for therapy resistance. As our understanding of cancer progresses, the need for precision medicine tailored to individual molecular targets has never been clearer.

The authors of the study further elucidate that targeting the FXR1-FUBP1 axis not only presents a viable strategy for enhancing chemotherapy efficacy but also raises the prospect of repurposing existing drugs used in other contexts. This approach could drastically reduce the time and cost associated with bringing new drugs to market, a significant advantage considering the urgent need for effective cancer therapies.

Emerging technologies such as CRISPR gene editing and RNA interference offer transformative tools that could be harnessed to disrupt the FXR1-FUBP1 interaction. Such advancements could lead to breakthroughs in preclinical and clinical settings, significantly contributing to our arsenal against chemotherapy-resistant LUSC.

As researchers continue to decode the complexities of cellular signaling and gene regulation, collaborations between biologists, pharmacologists, and oncologists will be critical. This multidisciplinary approach will facilitate the translation of laboratory findings into clinical practice, ensuring that discoveries made in the research setting can benefit patients in real-world scenarios.

This study serves as a compelling reminder of the persistent challenges in the realm of oncology. The findings presented by Liang and colleagues underscore the importance of sustained research efforts aimed at understanding the molecular underpinnings of cancer. The fight against LUSC and other malignancies is far from over, but studies like this offer hope and pave the way for innovative strategies that can improve patient outcomes.

In conclusion, the discovery of the FXR1-FUBP1 axis as a key player in chemotherapy resistance in LUSC cells is a significant leap forward in cancer research. These findings not only broaden our understanding of molecular interactions in cancer but also emphasize the urgency of developing therapeutic strategies to tackle this formidable disease. As the fight against cancer continues, every piece of information gained is a step closer to achieving effective treatments and ultimately, saving lives.

Subject of Research: The impact of the FXR1-FUBP1 axis on chemotherapy resistance in lung squamous cell carcinoma (LUSC).

Article Title: The Impact of the FXR1-FUBP1 Axis on Chemotherapy Resistance in LUSC Cells.

Article References:

Liang, R., Li, Y., Chen, J. et al. The Impact of the FXR1-FUBP1 Axis on Chemotherapy Resistance in LUSC Cells.
Biochem Genet (2025). https://doi.org/10.1007/s10528-025-11290-1

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10528-025-11290-1

Keywords: chemotherapy resistance, LUSC, FXR1, FUBP1, c-Myc, molecular biology, oncology.

Recent groundbreaking research conducted by a collaborative team of scientists from CNRS and Institut Curie has uncovered critical insights into the biological underpinnings of these persister cells. Their work, performed under the auspices of the “Dynamique de l’Information Génétique: Bases Fondamentales et Cancer” laboratory and Institut Curie’s Department of Translational Research, has demonstrated that persister cells across different patients exhibit a remarkably conserved transcriptional program. This genetic expression signature remains consistent irrespective of the diverse chemotherapy regimens patients have received, suggesting a common survival strategy employed by these cells.

Central to this persistence program is the pivotal role of regulatory molecules that orchestrate gene activity within the surviving cancer cells. Among these, the FOSL1 protein emerges as a molecular “on-off switch” that controls the cells’ entry into a drug-tolerant state. Unlike stable genetic mutations, this mechanism is reversible and non-genetic, providing persister cells with the flexibility to transiently alter their function and withstand chemotherapeutic pressure. Once the threat subsides, these cells can revert, underscoring the dynamic nature of cancer resistance.

The research team employed sophisticated sequencing technologies to investigate tumor biopsies sourced from eight TNBC patients and implanted them in mouse models to monitor tumor evolution and treatment response over time. This relatively large patient cohort, unprecedented in studies of this nature, allowed the scientists to capture a comprehensive portrait of the adaptive behaviors employed by persister cells at various disease stages. Their findings elucidate how these cells evade eradication, highlighting transcriptional programs and regulatory factors that govern therapeutic tolerance.

One of the most striking revelations of this study is the identification of a shared molecular framework orchestrating persistence, which transcends individual patient variability and specific drug treatments. This shared program represents a crucial target for intervention, as modulating the function of molecules like FOSL1 could weaken the cells’ shield against chemotherapy. Importantly, this approach could lead to therapeutic designs aimed not only at killing tumor cells but preemptively intercepting their transition into persistent states, tackling relapse at its root.

The implications of understanding the biology of persister cells extend well beyond scientific knowledge, pointing to tangible clinical applications. By translating these molecular insights into reliable biomarkers, physicians could potentially predict which patients harbor drug-tolerant cell populations prior to therapy commencement, allowing for personalized treatment adjustments. This predictive capacity would constitute a major leap forward in preventive oncology, steering efforts toward more proactive management rather than reactive responses to relapse.

Moreover, the delineation of reversible, non-genetic mechanisms governing drug tolerance challenges the traditional paradigm that attributes cancer relapse largely to irreversible genetic mutations. The plasticity offered by such regulatory programs implies that therapeutic resistance may be dynamically managed through modulating cellular states instead of solely focusing on mutational profiles. This insight opens exciting avenues for drug development that aim to manipulate cellular phenotype rather than genome alterations.

The study’s contribution is further amplified by its experimental model, combining patient-derived biopsies with in vivo mouse models to faithfully recapitulate the human tumor microenvironment. This strategy ensured that observations of persister cell behavior were not artifacts of cell culture but reflective of actual tumor biology. Sequencing of tumors at successive treatment points also revealed temporal changes in gene expression, enabling a detailed map of how resistance evolves and which molecular nodes are most critical over time.

In confronting one of the most aggressive breast cancer subtypes, this discovery shines a hopeful light on the future of cancer therapy. Targeting the molecular circuitry of persister cells could significantly diminish the risk of relapse that burdens TNBC patients. The ability to forestall or reverse the persistent state may render current chemotherapies more efficacious, transforming a difficult-to-treat cancer into one that is more manageable and less prone to deadly recurrence.

As with many pioneering findings, challenges remain in moving from bench to bedside. The research team underscores the need for further development of targeted agents against proteins like FOSL1 and the integration of transcriptomic signatures into clinical workflows. Such advances demand multi-disciplinary collaboration between basic scientists, clinicians, and pharmaceutical developers, united in the goal of delivering next-generation precision therapies for TNBC.

Looking ahead, the paradigm established by this research offers a blueprint for tackling drug resistance across diverse tumor types. The concept of targeting persister cells’ shared transcriptional programs may be broadly applicable, representing a universal strategy to mitigate cancer relapse. Harnessing this knowledge promises a future where therapeutic tolerance is no longer the Achilles’ heel of cancer treatment.

In summary, by elucidating the molecular basis of persister cell-mediated drug tolerance in triple-negative breast cancer, this study paves the way for innovative interventions aimed at preventing relapse. The identification of a conserved persistence program and its regulation by key proteins such as FOSL1 represents a milestone in understanding and ultimately combating therapeutic resistance. As this knowledge integrates into clinical practice, it offers renewed hope to patients facing one of the most challenging forms of breast cancer.

—
Subject of Research: Breast cancer, specifically triple-negative breast cancer and drug-tolerant persister cells
Article Title: Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients.
News Publication Date: 6-Nov-2025
Web References: DOI: 10.1158/0008-5472.CAN-25-0995
Image Credits: © Equipe Vallot – Institut Curie
Keywords: Breast cancer, Triple-negative breast cancer, Drug resistance, Persister cells, Chemotherapy tolerance, FOSL1, Cancer relapse, Tumor biology, Transcriptomic profiling, Precision oncology

Within solid tumors, aberrant vasculature leads to inefficient blood supply, depriving cells of oxygen and vital nutrients such as glucose. In parallel, increased metabolic demands and altered biochemical pathways result in the local accumulation of metabolic waste products that acidify the surroundings. This acidosis was historically viewed as a mere byproduct of tumor metabolism; however, emerging evidence positions it as a crucial regulatory factor influencing cancer cell physiology in profound ways. The present study employed cutting-edge CRISPR-Cas9 gene editing technology to conduct a comprehensive functional genomic screen aimed at deciphering how individual genes facilitate pancreatic cancer cell survival under distinct stress conditions including hypoxia, nutrient deprivation, and acidosis.

Researchers systematically knocked out each gene in cultured pancreatic cancer cells and quantitatively assessed impacts on cellular viability and growth rates. This meticulous approach, initially executed in vitro, was further extended in vivo by selectively silencing key candidate genes in genetically modified mouse models bearing pancreatic tumors. The comparative outcomes garnered from these complementary systems unveiled an unexpected insight: the metabolic architecture of cancer cells within tumors diverges significantly from conventional culture conditions and is dominantly shaped by the acidic milieu characteristic of the tumor microenvironment rather than by hypoxia or nutrient scarcity alone.

This distinction is pivotal, as it reinforces the view that acidosis functions as a master regulator, orchestrating metabolic adaptations that enable cancer cells to thrive. Specifically, acidification prompts a metabolic shift from reliance on glycolysis—the breakdown of glucose to derive energy—to enhanced mitochondrial respiration, a process more efficient for ATP production. Mitochondria, the cell’s power-generating organelles, typically present in fragmented forms within pancreatic cancer cells, undergo morphological transformations under acidic stress. The study reveals that acidic extracellular pH induces a fusion of mitochondrial fragments into expansive, interconnected networks, markedly augmenting their bioenergetic efficiency.

At the molecular level, this profound remodeling of mitochondrial architecture is mediated through the suppression of ERK signaling, a protein pathway heavily implicated in cell proliferation and metabolism. Under standard tumor conditions, elevated ERK activity favors mitochondrial fragmentation, thereby limiting their functional capacity. The acidosis-induced inhibition of ERK prevents this excessive division, facilitating mitochondrial fusion and enabling cells to utilize alternative metabolic substrates more effectively. When genetic interventions obstruct mitochondrial fusion, pancreatic cancer cells lose their ability to adjust metabolically, resulting in markedly impaired growth under acidic conditions.

These findings underscore a paradigm shift in our understanding of the tumor microenvironment’s role in cancer progression. Acidosis emerges not merely as a metabolic consequence but as an active and vital switch that governs energy homeostasis and survival strategies in tumor cells. The ability to pivot between glycolytic and oxidative phosphorylation pathways enables cancer cells to sustain their energy demands despite fluctuating environmental constraints, highlighting metabolic plasticity as a hallmark of malignant adaptation.

The implications for cancer therapy are profound. Targeting metabolic vulnerabilities that arise from the acidosis-driven reprogramming of mitochondrial dynamics offers a novel therapeutic angle. By disrupting the fusion processes or modulating ERK activity, it may be possible to impair cancer cells’ metabolic flexibility and render them more susceptible to conventional treatments. Indeed, this approach aligns with a growing emphasis on precision oncology strategies that exploit cancer-specific metabolic dependencies as opposed to universally cytotoxic agents.

This research also catalyzes further inquiries into the biochemical crosstalk between tumor acidity and cellular signaling networks. The intricate balance of mitochondrial fission and fusion serves as a central node integrating environmental cues with metabolic outputs, suggesting that other regulatory proteins and pathways may be involved. Expanding this knowledge could illuminate additional therapeutic targets and refine our capacity to manipulate tumor metabolism in clinical settings.

Moreover, the study highlights the limitations of traditional cell culture models in faithfully recapitulating the tumor microenvironment. Standard culture conditions, which lack the acidic stress prevalent in vivo, may misrepresent the metabolic state and behavior of cancer cells. This discrepancy reinforces the necessity of developing experimental systems that incorporate key environmental factors such as pH gradients to better model cancer biology and predict therapeutic outcomes.

The integration of sophisticated gene editing with precise environmental modulation exemplifies a powerful methodological advance in cancer research. It allows dissection of complex adaptive mechanisms at the genetic, cellular, and tissue levels, fostering a holistic understanding critical for innovation in cancer treatment. As the landscape of oncology moves toward increasingly targeted and mechanism-based interventions, such foundational studies provide indispensable insights.

Lead investigators Wilhelm Palm and Johannes Zuber point toward the broader significance of their findings, emphasizing that targeting tumor acidosis might extend beyond pancreatic cancer due to the ubiquitous nature of acidic environments in many solid tumors. Harnessing this knowledge could accelerate the development of metabolic-targeted cancer therapies capable of overcoming resistance mechanisms driven by the tumor microenvironment.

In summary, this seminal study reveals that tumor acidosis acts as a pivotal regulator of mitochondrial morphology and function, steering pancreatic cancer cells toward a metabolically efficient energy generation mode that supports their survival amidst hostile conditions. This acidosis-mediated metabolic adaptation offers promising new avenues for therapeutic intervention, potentially transforming the clinical management of pancreatic and other solid tumors resistant to current modalities.

Subject of Research: Pancreatic Cancer Cell Metabolism and Tumor Microenvironment Acidosis
Article Title: Acidosis Orchestrates Adaptations of Energy Metabolism in Tumors
News Publication Date: 2025
Web References: https://doi.org/10.1126/science.adp7603
References: Groessl S, Kalis R, Snaebjornsson MT, Wambach L, Haider J, Andersch F, Schulze A, Palm W, Zuber J. Acidosis orchestrates adaptations of energy metabolism in tumors. Science 2025, DOI 10.1126/science.adp7603
Image Credits: Groessl / German Cancer Research Center (DKFZ)
Keywords: Life Sciences, Cell Biology, Cancer Metabolism, Tumor Microenvironment, Acidosis, Mitochondrial Dynamics, Pancreatic Cancer, CRISPR-Cas9, Metabolic Adaptation